Diversity in Clinical Trials Boosted by New Law
by Neoteryx on March 6,2023
Did you know there is now a legal requirement for improving diversity in U.S. clinical trials?
According to a recent article by Jeannie Baumann on Bloomberglaw.com, part of a new Senate Bill includes the “Diverse Trials Act,” which requires diversity in clinical trials at the U.S. Food and Drug Administration (FDA).
The FDA has long worked to encourage diverse participation in clinical trials. People participating in clinical trials should represent the patients that will eventually use the medical products. Unfortunately, this is often not the case. Surveys show that people from racial and ethnic minorities and other diverse groups are underrepresented in clinical research.
Overcome Knowledge Gaps in Clinical Trials
The new bill, writes Baumann, aims to address decades of testing drugs primarily on White men. In recent years, White participation in clinical trials has ranged from 50%-90%. In contrast, Black or African American participation in clinical trials typically ranges from 5%-45%; Asian participation ranges from 0.75%-4%; and Hispanic or Latino participation ranges from 1%-2%. This has created gaps in knowledge on how drugs would work in a larger, more diverse population.
Baumann advises that drug and device companies should prepare “diversity action plans” to help them meet the new requirements for more diverse clinical trials, as stipulated under the 2023 spending bill.
The bill encourages research investigators to develop early strategies for reaching a broader, more diverse study population from the start as part of their clinical trial design. Having diversity built into the plan from the beginning helps to avoid failing the requirement or scrambling later in the trial process to try and comply.
For her article, Baumann interviewed bill sponsor Rep. Anna G. Eshoo (D-CA), who said, “This is the first time that there is a statutory requirement for diversity in clinical trials. The FDA has made efforts to encourage this since the 1980s, but it’s always been through voluntary guidance. This changes it.”
The draft guidance recommendations from the FDA include setting clinical trial enrollment goals based on the populations that are affected by a disease being studied in a clinical trial.
Several experts that Bauman interviewed for the article said that designing clinical trials should proceed with an understanding of their relevance, usefulness, and application at the end of the trial. They advised that moving forward, diversity action plans from companies and trial sponsors should effectively say, “Here’s who we want to reach and here’s our plan to reach them.”
Reach Broad, Diverse Study Populations
Clinical trial managers already find it challenging to recruit enough research volunteers. Bauman reports that more than 80% of clinical trials fail to enroll enough patients on time. Now Congress is asking them to enroll research volunteers with a focus on race and ethnicity, while also providing demographic information such as age, sex, geographic location, and socioeconomic status.
How can trial managers reach more diverse communities?
According to Donna M. O’Brien, a national adviser at Manatt Health, it is important to choose research sites that optimize enrollment, saying “If you want diverse populations, you have to go to the community.”
What if study volunteers could participate from home?
Decentralized clinical trials (DCTs) can be designed with remote enrollment and an option for remote specimen collection through sampling kits that are mailed to participants at home.
Study volunteers can use remote microsampling devices with easy-to-follow instructions & supplies in the kit boxes to self-collect blood samples.
They can mail their specimen samples to the research lab.
Follow-up visits can be virtual visits conducted online or via phone or video conference. The remote DCT approach removes the common barriers to clinical trial enrollment: travel, related costs, and inconvenience.
This is curated content. To read more about the bill encouraging diversity in clinical trials, read the original article at Bloomberglaw.com.
To learn more about Microsampling for Decentralized Clinical Trials, visit our DCT resource page, or view and download our DCT and microsampling infographic.
- Infectious Disease, Vaccines, COVID-19 (13)
- Mitra® Device (13)
- Company Press Release, Product Press Release (12)
- Clinical Trials, Clinical Research (9)
- Blood Microsampling, Serology (8)
- Decentralized Clinical Trial (DCT) (8)
- Research, Remote Research (7)
- Venipuncture Alternative (6)
- Industry News, Microsampling News (3)
- Antibodies, MAbs (1)
- Biomonitoring, Health, Wellness (1)
- Omics, Multi-Omics (1)
- Pharmaceuticals, Drug Development (1)
- Skin Microsampling, Microbiopsy (1)
- Toxicology, Doping, Drug/Alcohol Monitoring, PEth (1)
- March 2023 (2)
- February 2023 (1)
- January 2023 (2)
- December 2022 (1)
- November 2022 (1)
- October 2022 (2)
- September 2022 (1)
- August 2022 (1)
- April 2022 (1)
- February 2022 (1)
- January 2022 (1)
- December 2021 (1)
- November 2021 (1)
- October 2021 (2)
- September 2021 (1)
- August 2021 (2)
- July 2021 (2)
- June 2021 (2)
- April 2021 (1)
- March 2021 (2)
- February 2021 (1)
- January 2021 (1)
- December 2020 (1)
- November 2020 (1)
- October 2020 (1)
- September 2020 (2)
- August 2020 (3)
- July 2020 (3)
- June 2020 (2)
- May 2020 (1)
- April 2020 (3)
- October 2019 (1)
- March 2019 (1)
- January 2019 (1)
- November 2018 (1)
- August 2018 (1)
- July 2018 (1)
- December 2017 (1)
- June 2017 (2)
- April 2017 (1)
- March 2017 (1)
- February 2017 (1)
- May 2016 (1)
- December 2015 (1)
- October 2015 (1)
- August 2015 (1)
- August 2014 (1)
- July 2014 (1)
No Comments Yet
Let us know what you think